Alan Menter
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Immunology top 0.01%
- Psoriasis: Treatment and Pathogenesis
Papers in
- Immunology 311
- Psoriasis: Treatment and Pathogenesis 294
- Dermatology 132
- Dermatology and Skin Diseases 105
- Co-authors
- Mark Lebwohl (48 shared papers)Alice Bendix Gottlieb (39 shared papers)Steven R. Feldman (29 shared papers)John Y. M. Koo (24 shared papers)Kenneth B. Gordon (27 shared papers)Kim Alexander Papp (34 shared papers)Craig L. Leonardi (26 shared papers)James G. Krueger (16 shared papers)
- Journals
- Journal of the American Academy of Dermatology (106 papers)British Journal of Dermatology (35 papers)Journal of the European Academy of Dermatology and Venereology (17 papers)Dermatology and Therapy (17 papers)Journal of Dermatological Treatment (9 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Alan Menter
421 papers receiving 32.3k citations
Alan Menter's Hit Papers
Peers
Comparison fields: 5 of 164
- Dermatology 10.9k
- Immunology 23.5k
- Rheumatology 4.8k
- Hematology 2.3k
- Complementary and Manual Therapy 416
Countries citing papers authored by Alan Menter
This map shows the geographic impact of Alan Menter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Menter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Menter more than expected).
Fields of papers citing papers by Alan Menter
This network shows the impact of papers produced by Alan Menter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Menter. The network helps show where Alan Menter may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Menter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 427 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways Hit paper breakdown → | 2009 | 1194 |
| 2 | Guidelines of care for the management of psoriasis and psoriatic arthritis Hit paper breakdown → | 2008 | 1040 |
| 3 | The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Hit paper breakdown → | 2001 | 840 |
| 4 | Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis Hit paper breakdown → | 2012 | 819 |
| 5 | 2007 | 755 | |
| 6 | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Hit paper breakdown → | 2015 | 724 |
| 7 | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Hit paper breakdown → | 2015 | 709 |
| 8 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics Hit paper breakdown → | 2019 | 703 |
| 9 | Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis Hit paper breakdown → | 2010 | 700 |
| 10 | Guidelines of care for the management of psoriasis and psoriatic arthritis Hit paper breakdown → | 2008 | 661 |
| 11 | European S3‐Guidelines on the systemic treatment of psoriasis vulgaris Hit paper breakdown → | 2009 | 598 |
| 12 | A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci Hit paper breakdown → | 2008 | 566 |
| 13 | Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis Hit paper breakdown → | 2018 | 559 |
| 14 | Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial Hit paper breakdown → | 2009 | 505 |
| 15 | 1999 | 501 | |
| 16 | 2004 | 488 | |
| 17 | 2009 | 464 | |
| 18 | 2006 | 450 | |
| 19 | 2006 | 445 | |
| 20 | 2017 | 443 |
About Alan Menter
Alan Menter is a scholar working on Immunology, Dermatology, Pathology and Forensic Medicine, Rheumatology and Physiology, having authored 427 papers that have together received 33.8k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (294 papers), Dermatology and Skin Diseases (105 papers), Autoimmune Bullous Skin Diseases (49 papers), Health Systems, Economic Evaluations, Quality of Life (28 papers), Asthma and respiratory diseases (23 papers), Pharmaceutical studies and practices (23 papers), Spondyloarthritis Studies and Treatments (20 papers) and Autoimmune and Inflammatory Disorders Research (17 papers). The work is most often cited by research in Dermatology (10.9k citations), Immunology (23.5k citations), Rheumatology (4.8k citations), Hematology (2.3k citations) and Complementary and Manual Therapy (416 citations). Alan Menter has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Mark Lebwohl, Alice Bendix Gottlieb, Steven R. Feldman, John Y. M. Koo, Kenneth B. Gordon, Kim Alexander Papp, Craig L. Leonardi, James G. Krueger, Bruce E Strober and Caitriona Ryan. Their work appears in journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology, Journal of the European Academy of Dermatology and Venereology, Dermatology and Therapy and Journal of Dermatological Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.